Arabic Arabic English English French French German German
dark

Senhwa’s Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

Senhwa Biosciences, Inc. today announced that its oral new drug, Silmitasertib, had received a positive feedback from an Independent Data Monitoring Committee (DMC) Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Departure of Founder and CEO Heightens Uncertainty for Galapagos

Next Post

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Related Posts
Total
0
Share